Germany's health regulator has accused India's Alkem Laboratories of fudging data on clinical trials of an antibiotic and brain disorder drug. The drug, which is used to treat the neurological disorder amyotrophic lateral sclerosis, is now being reviewed by the European Medicines Agency. Earlier, India's GVK Biosciences and Quest Lifesciences were also found to have been misrepresenting data.